Accuray Incorporated · NASDAQ:ARAY
Accuray — Q3 FY2024 Earnings Presentation
13 slides from Accuray's earnings presentation, May 1, 2024
Slide 1: Q3'FY24 Earnings Call Supplemental Presentation
Q3’FY24 Earnings Call Supplemental Presentation May 1, 2024
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. 2 Proprietary and Confidential Property of Accuray Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are
Slide 3: Closing the Gaps to Cancer Care
Closing the Gaps to Cancer Care Advance Care by providing solutions that address the biggest pain points in RT Drive Patient Access to radiotherapy treatments in developed and high potential underserved markets Delight Customers by ensuring high operational performance so no patient is rescheduled H
Slide 4: Year History of Innovation
30 Year History of Innovation Helping to Set New Standards in Care for the Radiotherapy Industry First to offer ring gantry platform CyberKnife® Platform TomoTherapy®/ Radixact Platform First robotic SBRT delivery system First SRS/SBRT system to track and automatically adjust for motion in real time
Slide 5: Our Strategic Growth Plan: Key Pillars
Our Strategic Growth Plan: Key Pillars Guided by Our Vision: To expand the curative power of radiation therapy to improve as many lives as possible Grow revenue through innovation to advance care and expand access Operational excellence and efficiency Expand service revenue with installed base growt
Slide 6: Delivering on Improving Patient Access
Delivering on Improving Patient Access Solution Showcase at the China Medical Equipment Fair 2024 CyberKnife® System Tomo® C System Largest Healthcare and Medical Equipment Industry Show in China
Slide 7: Expanding Value Added Service Solutions
Expanding Value Added Service Solutions Advancing Care Through Global Training Network Proprietary and Confidential Property of Accuray Accuray Innovation & Partnership Hub - Genolier, Switzerland Incremental training revenue opportunity Existing training hubs in Madison, Wisconsin, Tokyo, Japan and
Slide 8: Q3'FY24 and YTD Q3'FY24 Financials
Q3’FY24 and YTD Q3’FY24 Financials Q3 Summary $M Q3 Y/Y YTD Y/Y Y/Y XFX2 YTD Y/Y XFX2 Gross Orders $89.1M 21% 23% $246.7M 11% 11% Revenues $101.1M (14%) (13%) $312.3M (5%) (6%) Product $49.6M (21%) (20%) $154.5M (10%) (10%) Service $51.5M (7%) (6%) $157.8M (1%) (1%) Op. Expenses $33.6M (8%) $110.8M
Slide 9: Adjusted FY24 Guidance
Adjusted FY24 Guidance Takes into account expectations regarding uncertainty and impact from macro environmental climate, FX and inflation Revenue Adjusted EBITDA1 FY24 Guidance Range $ in millions $432M - $437M $19M - $22M 1 Adjusted EBITDA is a non-GAAP measure. Please see Slide 13 for a reconcili
Slide 10: Thank you
ACCURAY Thank you
Slide 11: GAAP to Adjusted EBITDA Q3 FY'24 and Q3 FY'23 Actual
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization Three Months Ended March 31, 2024 Three Months Ended March 31, 2023 $ $ $ $ (6,342) 1,601 2,735 2,649 444 1,087 599 1,103 1,559 2,707 522 8,347 ERP and ER
Slide 12: GAAP to Adjusted EBITDA YTD Q3 FY24 and YTD Q3 FY23 Actual
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization Nine Months Ended March 31, Nine Months Ended March 31, 2023 2024 $ $ $ $ (18,932) 4,398 7,441 7,990 3,254 9,599 (6,724) 3,430 7,601 7,605 1,912 18,740 ER
Slide 13: GAAP to Adjusted EBITDA FY'24 Forward Looking Guidance
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization To From $ $ $ $ (17,400) 6,000 10,300 10,700 4,000 19,000 (14,400) 6,000 10,300 10,700 4,000 22,000 ERP and ERP related expenditures 2,800 2,800 GAAP to A